Recombinant Technology in
Transfusion Medicine.
Pp. 117-135.
The History, Mechanism and Clinical Use of Oral 5-Fluorouracil Derivative Chemotherapeutic Agents. Pp.137-164
Fumihiro Tanaka, Tatsuo Fukuse, Hiromi Wada* and Masakazu Fukushima
Characterization of Protein and Peptide Stability and Solubility in Non-Aqueous Solvents. Pp. 165-182.
Polymeric Contrast Agents for Medical Imaging. Pp. 183-215.
[Back to top] Recombinant Technology in Transfusion Medicine.
Recombinant
technology in transfusion medicine has really only just begun to have
large-scale impact. The preparation of blood products, determination of blood
group phenotype, detection of blood group specific antibodies does not
currently employ DNA-based methods for their preparation or detection. The
detection of blood-borne viruses, production of blood grouping reagents and
diagnosis of HLA polymorphism all include recombinant DNA-based technologies
and are beginning to impact on routine laboratory life in Transfusion medicine.
This review analyses the current use of recombinant technology in transfusion
medicine, and indicates where there is likely to be significant development of
this methodology (particularly in molecular diagnostics) oven the next decade
or so. The impact of molecular medicine in the field of transfusion has already
begun. Recent licensing of thrombopoietin for clinical use may have a profound
effect on the very high current demand for platelet transfusions. Gene therapy
protocols for the treatment of haemophilias and other coagulation disorders,
and the production of recombinant blood products may reshape the demand for
clotting factors from human plasma. I also consider the potential impact of the
exciting technologies of DNA arraying and nucleic acid therapeutics in the
fields of molecular diagnostics and the possible treatment of leukemia
respectively.
[Back to top] The History, Mechanism and Clinical Use of Oral 5-Fluorouracil Derivative Chemotherapeutic Agents.
Fumihiro Tanaka, Tatsuo Fukuse, Hiromi Wada*
and Masakazu Fukushima
The role of oral chemotherapy has been getting expanded because of the potential advantage in patients’ convenience and better quality of life as well as in cost-effectiveness as compared with intravenous chemotherapy. In this article, the history, mechanism of anti-tumor activity, and clinical use of oral chemotherapy using 5-fluorouracil (5-FU) derivative chemotherapeutic agents are reviewed. Pharmacological analysis has revealed that 5-FU, a basic chemotherapeutic agent widely used against a variety of malignant tumors, shows a time dependent anti-tumor activity, and that continuous maintenance of 5-FU concentration in blood is the optimal method in 5-FU administration. UFT, a combination drug of ftorafur (tetrahydrofuranyl-5-fluorouracil, tegafur, FT) and uracil, has been developed to have potent anti-tumor activity by maintaining higher 5-FU concentration in blood and tumor tissues for a long time. FT is a pro-drug that releases 5-FU continuously, and uracil is added to inhibit degradation of the released 5-FU. Clinically, oral administration of UFT has proved to be effective as an adjuvant therapy after surgery for some malignant tumors such as non-small cell lung cancer. Moreover, UFT has proved to be effective for inoperable advanced malignancies such as colorectal cancer, especially in combination with leucovorin or cisplatin. Recently, S-1, a more active oral 5-FU derivative chemotherapeutic agent has been developed in Japan. Several factors to affect anti-tumor effects and/or toxicities of 5-FU and the derivatives, such as thymidylate synthase activity, dehydropyrimidine dehydrogenase activity and p53 status, are also discussed in the article. In conclusion, oral administration of 5-FU derivatives such as UFT may have several clinical advantages over intravenous 5-FU administration.
[Back to top] Characterization of Protein and Peptide Stability and Solubility in Non-Aqueous Solvents.
Small molecule parenterals have often been formulated as solutions or suspensions in non-aqueous conditions, however, this technology has not found widespread use in the formulation of macromolecules. Formulation of proteins and peptides has primarily been achieved through aqueous solutions or reconstituted lyophilized cakes. The incorporation of non-aqueous techniques has been limited by the lack of general applicability. For example, prediction of solubility, chemical stability, conformational stability (unfolding/denaturation processes), and activity can be difficult. Therefore, macromolecule non-aqueous preformulation work must be performed on a case by case basis. In addition, only a few solvents are pharmaceutically acceptable. This article reviews the characterization of proteins and peptides in a variety of non-aqueous or co-solvent conditions (both acceptable and unacceptable for pharmaceutical applications), and discusses the applicability of non-aqueous conditions for increasing solubility, stability and activity.
[Back to top] Polymeric Contrast Agents for Medical Imaging.
Synthetic polymers and co-polymers are described, to be used as carriers of reporter groups for gamma-, magnetic resonance (MR), and computed tomography (CT) imaging. Those compounds include polychelating and amphiphilic polymers and serve as key components of various contrast agents. Single terminus-activated polychelating polymers were synthesized using poly-L-lysine (PLL) as a main chain and chelating moieties (such as diethylene triamine pentaacetic acid or DTPA) as side groups. These polymers were used for the modification of diagnostic monoclonal antibodies to increase their load with reporter metal atoms. As a result, better images within shorter time intervals were obtained in animal experiments. The application of liposomes and micelles as carriers for diagnostic imaging agents in experimental and clinical medicine is considered. The load of liposomes and micelles with contrast agents for gamma- and MR imaging (MRI) was sharply increased by using polychelating polymers additionally modified on one end with a hydrophobic phospholipid residue to give amphiphilic polymers. Such polymers easily incorporate the liposome membrane or micelle core and provide better loading of liposomes and micelles with reporter metals and, consequently, better and faster imaging of various physiological compartments, such as lymphatic and vascular systems. A block-copolymer of methoxy-poly(ethylene glycol) (MPEG) and iodine-substituted PLL was synthesized to prepare long-circulating contrast agent for CT imaging of the blood pool. In the aqueous solution, this copolymer forms stable and heavily loaded with iodine (up to 30% of iodine by weight) micelles. These micelle were successfully used for CT visualization of the vascular network in experimental animals. General trends in developing contrast polymers are discussed.